Shineco Announces Acquisition of Singapore Evolutionary Stem Cell Company
Shineco (NASDAQ: SISI) has announced the acquisition of a 51% stake in InfiniClone , a Hong Kong-based biotechnology company specializing in regenerative medicine and stem cell technology. The transaction, valued at $19,895,600 in cash plus 3,450,000 shares of Shineco common stock, was executed through Shineco's subsidiary, Shineco Life Sciences.
InfiniClone possesses 29 global patents across major markets including the US, Europe, and Asia. Their innovative technology claims to increase cell expansion throughput by 3-10x compared to existing methods and reduce production costs by over 60%. The company's proprietary methods could potentially reduce treatment preparation time for conditions like Parkinson's, Alzheimer's, and stroke from months to weeks.
The acquisition marks Shineco's strategic entry into stem cell technology and regenerative medicine, with the company aiming to accelerate InfiniClone's technology transition from laboratory to clinical applications.
Shineco (NASDAQ: SISI) ha annunciato l'acquisizione del 51% di InfiniClone, una società biotecnologica con sede a Hong Kong specializzata in medicina rigenerativa e tecnologia delle cellule staminali. L'operazione, del valore di 19.895.600 dollari in contanti più 3.450.000 azioni ordinarie di Shineco, è stata realizzata tramite la controllata Shineco Life Sciences.
InfiniClone detiene 29 brevetti globali nei principali mercati, tra cui Stati Uniti, Europa e Asia. La loro tecnologia innovativa promette di aumentare la produttività dell'espansione cellulare da 3 a 10 volte rispetto ai metodi attuali, riducendo i costi di produzione di oltre il 60%. I metodi proprietari dell’azienda potrebbero ridurre i tempi di preparazione dei trattamenti per patologie come Parkinson, Alzheimer e ictus da mesi a settimane.
L'acquisizione segna l'ingresso strategico di Shineco nella tecnologia delle cellule staminali e nella medicina rigenerativa, con l’obiettivo di accelerare la transizione della tecnologia di InfiniClone dal laboratorio alle applicazioni cliniche.
Shineco (NASDAQ: SISI) ha anunciado la adquisición del 51% de InfiniClone, una empresa biotecnológica con sede en Hong Kong especializada en medicina regenerativa y tecnología de células madre. La transacción, valorada en 19.895.600 dólares en efectivo más 3.450.000 acciones ordinarias de Shineco, se realizó a través de la subsidiaria Shineco Life Sciences.
InfiniClone posee 29 patentes globales en mercados clave como Estados Unidos, Europa y Asia. Su tecnología innovadora afirma aumentar la producción de expansión celular entre 3 y 10 veces en comparación con los métodos actuales, y reducir los costos de producción en más del 60%. Los métodos exclusivos de la compañía podrían reducir el tiempo de preparación del tratamiento para enfermedades como Parkinson, Alzheimer y accidente cerebrovascular de meses a semanas.
La adquisición representa la entrada estratégica de Shineco en la tecnología de células madre y medicina regenerativa, con el objetivo de acelerar la transición de la tecnología de InfiniClone del laboratorio a aplicaciones clínicas.
Shineco (NASDAQ: SISI)는 재생 의학 및 줄기세포 기술을 전문으로 하는 홍콩 기반의 바이오테크 기업 InfiniClone의 지분 51%를 인수했다고 발표했습니다. 이번 거래는 1,989만 5,600달러의 현금과 Shineco 보통주 345만 주로 구성되었으며, Shineco의 자회사인 Shineco Life Sciences를 통해 진행되었습니다.
InfiniClone은 미국, 유럽, 아시아 등 주요 시장에서 29건의 글로벌 특허를 보유하고 있습니다. 이들의 혁신적인 기술은 기존 방법에 비해 세포 확장 생산성을 3~10배 향상시키고 생산 비용을 60% 이상 절감할 수 있다고 주장합니다. 회사의 독자적인 방법은 파킨슨병, 알츠하이머, 뇌졸중과 같은 질환의 치료 준비 기간을 수개월에서 수주로 단축할 가능성이 있습니다.
이번 인수는 Shineco가 줄기세포 기술 및 재생 의학 분야에 전략적으로 진출하는 것을 의미하며, InfiniClone의 기술을 연구실에서 임상 응용으로 빠르게 전환하는 것을 목표로 하고 있습니다.
Shineco (NASDAQ : SISI) a annoncé l'acquisition de 51 % des parts de InfiniClone, une société biotechnologique basée à Hong Kong spécialisée dans la médecine régénérative et la technologie des cellules souches. La transaction, d'une valeur de 19 895 600 dollars en espèces ainsi que 3 450 000 actions ordinaires de Shineco, a été réalisée via la filiale Shineco Life Sciences.
InfiniClone détient 29 brevets mondiaux sur des marchés clés tels que les États-Unis, l’Europe et l’Asie. Leur technologie innovante prétend augmenter la production d’expansion cellulaire de 3 à 10 fois par rapport aux méthodes existantes et réduire les coûts de production de plus de 60 %. Les méthodes propriétaires de l’entreprise pourraient réduire le temps de préparation des traitements pour des maladies telles que Parkinson, Alzheimer et les AVC, passant de plusieurs mois à quelques semaines.
Cette acquisition marque l’entrée stratégique de Shineco dans la technologie des cellules souches et la médecine régénérative, avec pour objectif d’accélérer la transition de la technologie d’InfiniClone du laboratoire aux applications cliniques.
Shineco (NASDAQ: SISI) hat den Erwerb von 51 % der Anteile an InfiniClone bekannt gegeben, einem biotechnologischen Unternehmen mit Sitz in Hongkong, das sich auf regenerative Medizin und Stammzelltechnologie spezialisiert hat. Die Transaktion, bewertet mit 19.895.600 US-Dollar in bar zuzüglich 3.450.000 Aktien von Shineco, wurde über die Tochtergesellschaft Shineco Life Sciences abgewickelt.
InfiniClone besitzt 29 weltweite Patente in wichtigen Märkten wie den USA, Europa und Asien. Die innovative Technologie soll die Zellvermehrung um das 3- bis 10-fache gegenüber bestehenden Methoden steigern und die Produktionskosten um über 60 % senken. Die firmeneigenen Verfahren könnten die Vorbereitungszeit für Behandlungen bei Krankheiten wie Parkinson, Alzheimer und Schlaganfall von Monaten auf Wochen verkürzen.
Die Übernahme markiert den strategischen Einstieg von Shineco in die Stammzelltechnologie und regenerative Medizin, mit dem Ziel, den Technologietransfer von InfiniClone vom Labor in die klinische Anwendung zu beschleunigen.
- Acquisition of 51% stake provides immediate entry into high-value regenerative medicine market
- Portfolio of 29 global patents across major markets ensures strong intellectual property protection
- Technology claims 60% cost reduction in cell production
- 3-10x improvement in cell expansion throughput efficiency
- Significant reduction in treatment preparation time from months to weeks
- Substantial cash outlay of $19,895,600 impacts company's cash reserves
- Share dilution due to issuance of 3,450,000 new common shares
- Technology benefits still in development phase, not yet proven in clinical settings
Insights
Shineco's acquisition of InfiniClone represents a major financial commitment at 1.5x their market cap with significant dilution for existing shareholders.
Shineco's acquisition of a 51% stake in InfiniClone represents a major financial commitment and strategic pivot. The deal terms -
This transaction structure raises immediate questions about financing. The cash component alone exceeds Shineco's entire market capitalization, though the article doesn't disclose how this will be funded. Additionally, the equity component will result in significant dilution for existing shareholders, as 3.45 million new shares represents a substantial increase to the existing share count.
The acquisition marks Shineco's entry into the regenerative medicine field, a substantial departure from its current focus on diagnostic medical products. While InfiniClone's patent portfolio (29 global patents) suggests strong intellectual property protection, the article provides no information about InfiniClone's current revenue, development stage, or timeline to commercialization.
From a financial perspective, this represents a transformative bet for Shineco, with the acquisition valued at more than 1.5x its current market cap. Without details on InfiniClone's financial metrics or commercialization status, assessing the potential return on investment remains challenging. The transaction suggests Shineco sees tremendous value potential in InfiniClone's technology, but also introduces substantial execution risk as they work to integrate and commercialize these new capabilities.
Shineco acquires promising stem cell technology with efficiency claims that could revolutionize treatment of neurological conditions if clinically validated.
Shineco's acquisition of a majority stake in InfiniClone signals a strategic expansion into regenerative medicine focused on induced pluripotent stem cell (iPSC) technology. InfiniClone's intellectual property position appears substantial, with 29 global patents spanning major markets including the US, Europe, and Asia.
The company's core technological advantages center on scalability and efficiency improvements in stem cell production. Their microcarrier technology and iPSC library management approaches reportedly increase cell expansion throughput by 3-10x while reducing production costs by over
Particularly noteworthy is InfiniClone's claim regarding accelerated production timelines for treating neurological conditions like Parkinson's, Alzheimer's, and stroke. The ability to produce functional neurons in weeks rather than months could significantly impact treatment accessibility if these claims are validated in clinical settings.
The technical leadership appears credible, with Dr. Lim Kah Meng bringing over 20 years of relevant research experience and a track record of founding multiple biotechnology companies. However, the article doesn't mention clinical validation status, regulatory approvals, or commercialization timelines - all critical factors in the stem cell therapy landscape.
This acquisition represents Shineco's entry into a highly specialized field with different regulatory pathways and commercialization challenges than their existing diagnostic products business. While the technology shows promise, the path from laboratory to approved clinical applications typically involves extensive validation, regulatory review, and capital investment not addressed in the announcement.
Expanding the Frontiers of Regenerative Medicine
BEIJING, April 23, 2025 (GLOBE NEWSWIRE) -- Shineco, Inc. ("Shineco" or the "Company"; NASDAQ: SISI), a provider of innovative diagnostic medical products and related medical devices, announced today that on April 22, 2025, its subsidiary, Shineco Life Sciences Group Hong Kong Limited ("Shineco Life Sciences"), entered into a Share Purchase Agreement (the "SPA") with Dr. Lim Kah Meng (the "Seller") to acquire
Pursuant to the SPA, Shineco Life Sciences will acquire a
InfiniClone has 29 global patents, including five invention patents, that cover major markets such as the US, Europe (the UK, Germany, France and Switzerland), and Asia (Japan, China and Singapore), which it believes gives it a competitive advantage in the field of stem cell technology. Its core technologies include cell reprogramming technology, stem cell culture based on microcarrier technology, and the establishment and management of induced pluripotent stem cells (iPSC) libraries, which it believes can increase the throughput of cell expansion by three to ten times that of existing technologies. While traditional stem cell cultures rely on expensive manual operations and consumables, InfiniClone believes its technology has the potential to significantly reduce labor and material inputs, reducing the production cost per cell by more than
InfiniClone's founder, Dr. Lim Kah Meng, is a Doctor of Biomedical Sciences from the National University of Singapore and is a Singaporean scientist, entrepreneur and biomedical expert with over 20 years of molecular research experience in stem cell research, regenerative medicine and neuro medicine therapies. In addition, Dr. Lim is the founder of a number of biotechnology companies, including Gene Oasis PTE. LTD., Zenzic Oasis PTE. LTD., BetaLife PTE. LTD. and CanniOasis PTE. LTD. with these companies having a differentiated focus on cell therapy, stem cell production and personalized medicine.
Jennifer Zhan, the CEO of Shineco, commented, "The acquisition of a majority position of InfiniClone is a key milestone for Shineco as it launches our entry into the field of stem cell technology and regenerative medicine. InfiniClone’s unique technology, global patent protection and Dr. Lim's professional capabilities represent core competitiveness in a high-value-added medical space, and we believe that Shineco can accelerate the transformation process of InfiniClone’s technology from laboratory to clinic. We look forward to working together with InfiniClone to solve the treatment problems of Parkinson's, Alzheimer’s, stroke, and other major diseases, and provide innovative solutions for patients around the world.”
More complete information of the SPA is set forth in the Form 8-K and its exhibits filed with the Securities and Exchange Commission on April 23, 2025.
About Shineco Corporation
Shineco Inc. ("Shineco" or the "Company") aims to "focus on healthy living and improve the quality of life" by providing safe, efficient and high-quality health and medical products and services to society. Shineco, operating through subsidiaries, has researched and developed 33 kinds of in vitro diagnostic reagents and related medical devices to date, and the Company also produces and sells healthy and nutritious foods. For more information about Shineco, please visit www.biosisi.com/.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by words such as "may," "will," "should," "could," "intend," "expect," "plan," "budget," "forecast," "anticipate," "believe," "estimate," "forecast," "potential," "continue," "evaluate" or similar words. Forward-looking statements should not be relied upon as they are neither historical facts nor guarantees of future performance. Rather, they are based solely on our current beliefs, expectations and assumptions about future business, future plans and strategies, forecasts, expected events and trends, economics, and other future conditions. Examples of forward-looking statements include, among other things, our innovation and market position in our products and services, our competitive advantages, and our expectation that the 5-minute cardiac test will be one of the leading products in this field to meet the need for test results immediately upon intake. Please do not rely on any forward-looking statements. Actual results may differ materially from those indicated in historical results or forward-looking statements due to various factors, including, but not limited to, the Company's ability to raise additional capital, its ability to maintain and grow its business, the variability of its results of operations, its ability to maintain and enhance its brand, its ability to develop and introduce new products and services, its ability to obtain all necessary regulatory approvals in the jurisdictions in which it intends to market and sell its products, Companies to be acquired, Successful integration of technology and assets into its portfolio of products and services Marketing and other business development initiatives Industry competition, general government regulations, economic conditions, impact of the COVID-19 pandemic, reliance on key personnel, attracting, hiring and retaining personnel with the technical skills and experience required to meet customer requirements and protect intellectual property. Shineco encourages you to review other factors that may affect its future performance in its filings with the Securities and Exchange Commission. The forward-looking statements in this press release are based only on information currently available to us and are made only as of the date of this press release, and Shineco undertakes no obligation to update any forward-looking statements, except as required by applicable rules and regulations.
For more information, please contact:
Shineco, Inc.
secretary@shineco.tech
Mobile: +86-010-68130220
Precept Investor Relations LLC
David J. Rudnick
david.rudnick@preceptir.com
Mobile: +1-646-694-8538
FAQ
What is the total value of Shineco's (SISI) acquisition of InfiniClone?
How many patents does InfiniClone hold and in which markets?
What cost reduction does InfiniClone's stem cell technology claim to achieve?
How will SISI's acquisition of InfiniClone impact treatment times for neurological conditions?
What is the efficiency improvement claimed by InfiniClone's cell expansion technology?
